Cargando…

Effectiveness of Soluble CTLA-4-Fc in the Inhibition of Bone Marrow T-Cell Activation in Context of Indoleamine 2.3-Dioxygenase (IDO) and CD4(+)Foxp3(+) Treg Induction

BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease with systemic inflammation finally resulting in damaged joints. One of the RA development models suggests bone marrow (BM) as a place of inflammation development further leading to disease progression. We aimed to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massalska, Magdalena, Ciechomska, Marzena, Kuca-Warnawin, Ewa, Burakowski, Tomasz, Kornatka, Anna, Radzikowska, Anna, Pawlak, Dariusz, Muz, Barbara, Loniewska-Lwowska, Adrianna, Palucha, Andrzej, Maldyk, Pawel, Maslinski, Wlodzimierz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792113/ https://www.ncbi.nlm.nih.gov/pubmed/36578517 http://dx.doi.org/10.2147/JIR.S359775

Ejemplares similares

Circulating miRNA Correlates with Lipid Profile and Disease Activity in Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients
por: Bonek, Krzysztof, et al.
Publicado: (2022)

Rheumatoid arthritis bone marrow environment supports Th17 response
por: Kuca-Warnawin, Ewa, et al.
Publicado: (2017)

CD4(+)FOXP3(+) T Cells in Rheumatoid Arthritis Bone Marrow Are Partially Impaired
por: Massalska, Magdalena, et al.
Publicado: (2020)

Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022)

The Kinetics of Humoral and Cellular Responses after the Booster Dose of COVID-19 Vaccine in Inflammatory Arthritis Patients
por: Wroński, Jakub, et al.
Publicado: (2023)

Different expression of chemokines in rheumatoid arthritis and osteoarthritis bone marrow
por: Kuca-Warnawin, Ewa H., et al.
Publicado: (2016)

Toll-like receptor 9 agonists and IL-15 promote activation, proliferation, secretion of proinflammatory cytokines and differentiation of B cells isolated from bone marrow of rheumatoid arthritis patients
por: Rudnicka, W, et al.
Publicado: (2007)

The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis
por: Kurowska, Weronika, et al.
Publicado: (2017)

Different Secretory Activity of Articular and Subcutaneous Adipose Tissues from Rheumatoid Arthritis and Osteoarthritis Patients
por: Plebańczyk, Magdalena, et al.
Publicado: (2018)

Bone marrow as a secondary lymphoid organ: mature T-cell subsets in bone marrow from rheumatoid arthritis and osteoarthritis patients
por: Warnawin, E, et al.
Publicado: (2005)

Distinct lymphocyte subpopulations in bone marrow from rheumatoid arthritis and osteoarthritis patients: a role for IL-15?
por: Maslinski, W, et al.
Publicado: (2004)

Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
por: Massalska, Magdalena, et al.
Publicado: (2020)

Monocyte-related biomarkers of rheumatoid arthritis development in undifferentiated arthritis patients – a pilot study
por: Kurowska, Weronika, et al.
Publicado: (2018)

Basic Properties of Adipose-Derived Mesenchymal Stem Cells of Rheumatoid Arthritis and Osteoarthritis Patients
por: Kuca-Warnawin, Ewa, et al.
Publicado: (2023)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
por: Bonek, Krzysztof, et al.
Publicado: (2021)

Functional Toll-like receptor 9 modulates the activity of bone marrow B cells isolated from rheumatoid arthritis patients
por: Rudnicka, W, et al.
Publicado: (2005)

Circulating miRNA-19b as a biomarker of disease progression and treatment response to baricitinib in rheumatoid arthritis patients through miRNA profiling of monocytes
por: Ciechomska, Marzena, et al.
Publicado: (2023)

DNA Methylation as a Future Therapeutic and Diagnostic Target in Rheumatoid Arthritis
por: Ciechomska, Marzena, et al.
Publicado: (2019)

Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
por: Huang, Guanyou, et al.
Publicado: (2012)

Associations of IL-18 with Altered Cardiovascular Risk Profile in Psoriatic Arthritis and Ankylosing Spondylitis
por: Bonek, Krzysztof, et al.
Publicado: (2022)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Impact of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Rheumatic Disease Patients on T Helper Cell Differentiation
por: Kuca-Warnawin, Ewa, et al.
Publicado: (2022)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis
por: Mancuso, Roberta, et al.
Publicado: (2015)

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
por: Arinola, Ganiyu Olatunbosun, et al.
Publicado: (2023)

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus
por: Reinhart, Bonnie, et al.
Publicado: (2012)

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
por: Tang, Kai, et al.
Publicado: (2021)

Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease
por: Wongpraparut, Nattawut, et al.
Publicado: (2021)

Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice
por: Affolter, Timothy, et al.
Publicado: (2019)

Virus‐Like Particles: Models for Assembly Studies and Foreign Epitope Carriers
por: Palucha, Andrzej, et al.
Publicado: (2005)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG(35-55)-induced experimental autoimmune encephalomyelitis
por: Wetzel, Lisa A., et al.
Publicado: (2020)

Is the variant c.422+90G→A in intron 4 of indoleamine 2, 3 -dioxygenase (IDO) gene related to age related cataracts?
por: Mamata, M., et al.
Publicado: (2011)

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
por: Röhrig, Ute F., et al.
Publicado: (2022)

Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme
por: Pallotta, Maria Teresa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jvdp71lj7186b0p288ir724vvj